The immune systems of cancer patients are highly disrupted, with those who have a higher number of immune cells in their ...

Cells treated with ibrutinib and acalabrutinib each had a unique set of 13 m/z signals, which opens up the possibility of studying these metabolites as biomarkers of therapeutic response.

The immune systems of cancer patients are highly disrupted, with those who have a higher number of immune cells in their blood having a better survival rate, finds a new study that uses a pioneering ...

Panelists discuss exciting updates on Bruton tyrosine kinase (BTK) inhibitors from the 2024 American Society of Hematology ...

The CRISTALLO trial showed that venetoclax plus obinutuzumab achieved high minimal residual disease negativity as a frontline ...

In the subgroup with 17p deletion or TP53 mutation, zanubrutinib outperformed others with the most favorable HR (0.52) and the highest SUCRA value of 97%.

Expert Rev Hematol. 2013;6(4):441-449. In conclusion, although age should generally determine the goal of treatment in CLL, the patient's functional status rather than chronological age can be ...

Judy Perkins’ stage 4 cancer was eradicated after she joined a clinical trial for T-cell therapy ... good luck treating melanoma patients and patients with blood cancers like leukaemia and ...

A low white blood cell count may or may not cause symptoms, but can result in serious health complications since you have fewer disease-fighting blood cells. There are several types of leukopenia, ...

Insulin works by moving glucose from your blood into your cells. There, you either use it for fuel right ... or frequent urination. Centers for Disease Control and Prevention. Manage Blood Sugar.